O’ still small voice of calm

Later today we will see the much anticipated first look at the initial data from Relay on their selective FGFR2 inhibitor, RLY–4008. Their poster on the PI3Kα inhibitor, RLY–2608 was made available in the ePoster hall yesterday.

Ahead of the presentation in the second plenary session, we take a look at some of the issues and challenges to think about.

This is especially key since this is a first-in-human phase 1 trial, meaning the dose escalation portion of the study where the focus is on tolerability and safety, and where it also behooves us to look at the broader picture in this context rather than indulge in breathless hype.

BSB subscribers can read up on our latest commentary and analysis from the cancer conference season on our TRIPLE meeting coverage – you can log-in or click to access our latest analysis.

This content is restricted to subscribers

Posted by